Baird Maintains Outperform on Instil Bio, Lowers Price Target to $54
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Jack Allen has maintained an Outperform rating on Instil Bio (NASDAQ:TIL) but has reduced the price target from $100 to $54.
January 17, 2024 | 7:34 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Instil Bio's price target has been lowered from $100 to $54 by Baird, although the Outperform rating is maintained.
The reduction in the price target for Instil Bio by a significant margin suggests that Baird sees less upside potential than before, which could lead to a negative short-term reaction in the stock price. However, the maintenance of the Outperform rating indicates that the overall outlook remains positive.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100